Rockville, MD – April 27, 2016 – MockV Solutions, Inc. (MockV or the Company), a biotechnology company developing non-infectious viral clearance prediction products that address the unmet needs of process development scientists as they establish biopharmaceutical manufacturing platforms, announced today that it has been invited to present preliminary results from proof of concept studies of its lead product, the MVMMVP Kit, at Cambridge Health Institute’s (CHI) annual BioProcess Summti on August 15 – 19, 2016 in Boston, MA.
A poster displaying the results will be available for viewing throughout the conference and an oral presentation will be given by MockV CEO – David Cetlin – on Friday, August 19, 2016 at 9:30 am in the Virus and Pathogen Clearance and Safety in Biologics track. The presentation and poster will introduce the concept of utilizing Mock Virus Particle (MVP) technology for predicting live Minute Virus of Mice (MVM) clearance results during downstream bioprocess development and will outline results from an anion exchange and virus filtration spiking study.
Poster and Oral Presentation Titles:
• Characterization and Use of a Mock Virus Particle as Spiking Surrogates for Downstream Process Development Studies
About CHI’s BioProcessing Summit
The Bioprocessing Summit brings together international leaders to discuss today’s bioprocess issues from cell line selection to bioproduction. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking. This leading bioprocess meeting is hosted in Boston each summer along the lively and cosmopolitan harbor waterfront. Each year, the international bioprocessing community comes together at the Summit to share practical solutions for today’s bioprocess challenges with researchers from around the world. Spanning five days, the 2016 meeting includes 16 conference programs, 9 training seminars, and 10 short courses. More details about the conference can be found at http://www.giiconference.com/chi351314/